We investigated whether measuring the excretion of each acute kidney injury (AKI) biomarker after cisplatin (CDDP) administration is useful for predicting AKI and evaluated the most appropriate AKI marker in patients treated with CDDP.
We measured NAG, Kim-1, and NGAL in urinary samples of 40 cancer patients treated with chemotherapy on day 1 (before chemotherapy), day 2, and day 5 after treatment; serum creatinine (sCr) was compared on days 7 and 28 after CDDP administration vs. baseline.
NAG, Kim-1, and NGAL excretion (creatinine corrected) were not significantly elevated 5 days after receiving chemotherapy in the non-CDDP chemotherapy group. Conversely, all markers were significantly higher 5 days after receiving chemotherapy in the CDDP group when compared to baseline.
Urinary NAG, Kim-1, and NGAL can detect renal injury more sensitively than sCr.
Anticancer research. 2017 Sep [Epub]
Akimitsu Maeda, Hitoshi Ando, Takashi Ura, Kei Muro, Masahiro Aoki, Ken Saito, Eisaku Kondo, Shinji Takahashi, Yuko Ito, Yasunari Mizuno, Akio Fujimura
Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan ., Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, Japan., Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan., Division of Molecular Pathology, Aichi Cancer Center Research Institute, Nagoya, Japan., Division of Molecular and Cellular Pathology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan.